Unscrew the needle and put it in a sharps container
Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation
Dietary modification represents an important strategy for managing sulfur burps while taking GLP-1 medications
This is dramatically shorter than commercial medications because: There is no FDA-regulated expiration date Stability depends on compounding quality Each pharmacy uses different preservatives, bases, and processes Improper sterilization shortens beyond-use timelines Adding B12 (even though beneficial) can alter stability if done incorrectly This means: A compromised tirzepatide vial is not uncommon
MOTS-C in particular degrades more rapidly than many other peptides once reconstituted
Loss of weight, sodium and water in obese persons consuming a high- or low-carbohydrate diet